Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 6/20 | 0.45 |
| ▸ | TTR | P02766 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | RBP4 | P02753 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15627271 | 1.00 | SCD (0.45) | SCDTTREPHX2RBP4CYP2D6 | |
| SCHEMBL19527510 | 0.83 | EPHX2 (0.45) | SCDTTREPHX2RBP4CYP2D6 | |
| SCHEMBL15611503 | 0.83 | SCD (0.45) | SCDEPHX2RBP4CYP2D6CYP3A4 | |
| SCHEMBL15611502 | 0.83 | SCD (0.45) | SCDEPHX2RBP4CYP2D6CYP3A4 | |
| SCHEMBL19308484 | 0.82 | SCD (0.42) | SCDTTREPHX2RBP4CYP2D6 | |
| SCHEMBL1230447 | 0.81 | SLC6A2 (0.54) | SCDSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL3951369 | 0.79 | SLC6A2 (0.53) | SCDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2298452 | 0.77 | SCD (0.49) | SCDTTRRBP4CYP2D6CYP3A4 | |
| SCHEMBL18610899 | 0.77 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18610905 | 0.77 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751877-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2017-09-05 | — | — | US | disclosed |